1.Clinical study of salbutamol combined with magnesium sulfate by nebulization in the treatment of paroxysmal asthma
Changqiong XU ; Jing YANG ; Xingke MENG ;
Chinese Journal of Clinical Pharmacology and Therapeutics 2002;0(05):-
AIM: To explore the efficacy of salbutamol combined with magnesium sulfate by nebulization in the treatment of paroxysmal asthma. METHODS: All of 75 asthma patients were divided into three groups of A, B, and C (n=25): A group treated with 3 ml of 7.5 % isoosmotic magnesium sulfate solution and 3 ml of physiology saline 5 minutes later; B group treated with 3 ml of 0.1 % salbutamol solution and 3 ml of Physiology saline 5 minutes later; C group treated with 3 ml of 0.1 % salbutamol solution and 3 ml of 7.5 % isoosmotic magnesium sulfate solution 5 min later. Forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF) in the three groups were tested before and after the treatment 15 min respectively; systolic, diastolic, heart rates and respirations were tested between group A and group C as well. RESULTS: Significant differences were found in ratios (FVC%, FEV1%, PEF%) of actual indexes of lung function (FVC, FEV1, PEF) to the predicted indexes between before and after treatment in the three groups (P
2.Association between a genomic polymorphlsm within the CD14 locus and severe sepsis susceptibility as well as outcome in postoperation
Changqiong XU ; Wei WANG ; Huaining WANG ; Dehong LIU ; Xiaoling FENG
Chinese Journal of Primary Medicine and Pharmacy 2008;15(3):353-354
Objective To investigate the relation of a lipopolysaccharide receptor CD14C-159T gene polymorphism to severe sepsis susceptibility and outcome in postoperation.Methods A prospective,consecutive entry study WSS made among 42 postoperative severe sepsis admitted in neurosurgeon,and 50 health volunteers.The genomic DNA of peripheral blood nucleated was extracted.Typing of each patient for the CD14-159C/T gene polymorphism was performed by restrictive fragment length polymorphism(RFLP).Genotypes were then related to the susceptibility and mortality rate of severe sepsis.Results Development of postoperative severe sepsis increased in patients homozygous for the allele T(78.4%)than that of the allele C(21.6%)(P<0.05).The mortalitv of sepsis were significantly higher in patients with CD14 homozygous for the T allete(TT)(84.6%)than those with genotype TC (15.4%)and C ailetc(CC)(O).Conclusion The single base pair polymorphism at position-159 in the CD14 gene promoter might influence the development of severe sepsis as well as outcome in postopration.
3.Association between a genomic polymorphism within the CD14 locus and severe sepsis outcome as well as cytokines
Changqiong XU ; Wei WANG ; Huaining WANG ; Dehong LIU ; Xiaoling FENG
Journal of Chinese Physician 2009;11(1):45-47
Objective To investigate the relation of a lipopolysaecharide receptor CDl4C-159T gene polymorphism to severe sepsis outcome and cytokines in postoperative severe sepsis.Methods A prospective,consecutive entry study was made among 42 postoperative sevel'e sepsis admitted in neurosurgeon department,Second People~Hospital ShenZhen between Feb.2007 to Jul.2007.The genomie DNA of peripheral blood nucleated cells WaS extracted.CDl4-159C/T gene polymorphism patients was detected by restrictive fragment length polymorphism(RFLP)analysis.The relationship between genotypes and the production of eytokines TNF-α,IL-6,IL-10 and mortality rate of severe sepsis were evaluated.Results The mortality of sepsis in patients with CDl4 homozygous for the T allete(Tr)(69.2%)was significanfly higher than those with genotype CT(23.1%)and C allete(CC)(7.7%).In addition,TNF-a and IL-6 production ofTI'homozygore were markedly higher than those of the TC and CC genetypes.while IL-10 production were the lowest of the three(P<0.05).Conclusion The single base pair pelymorphism at position-159 in the CD14 gene promoter might influence the outcome of severe sepsis and may be related to production of pro-inflammatory cytokines TNF-α,IL-6,and decrease the anti-inflanunatiry factor IL-10.